Evidence map›Paper›PMID 38132670›Full record

ArticlemSystems2024

Phenotypes of a

Sophia H Nozick, Egon A Ozer, Rachel Medernach, Travis J Kochan, Rebecca Kumar, Jori O Mills, Richard G Wunderlink, Chao Qi, Alan R Hauser

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Article
  6. Cytotoxicity and virulence attributes ofRespiratory medicine case reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sophia H NozickDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-0791-6340
Egon A OzerDepartment of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Rachel MedernachDepartment of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Travis J KochanDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Rebecca Kumar4Department of Medicine, Division of Infectious Diseases, Georgetown University, Washington, DC, USA.
Jori O MillsDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Richard G WunderlinkDepartment of Medicine, Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Chao QiDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Alan R HauserDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-4596-7939
Northwestern University · USGeorgetown University · US

Funding

Technology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JUSTIN B. STARREN · 2018 to 2026
$24.7M
TRAINING PROGRAM IN IMMUNOLOGY &MOLECULAR PATHOGENESIST32AI007476 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Edward Benjamin Thorp · 1996 to 2026
$6.6M
Population Analysis of Pseudomonas aeruginosa VirulenceR01AI118257 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2016 to 2025
$4.9M
Translational Research Training in Infectious DiseasesT32AI095207 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Claudia A Hawkins, Jennie H Kwon · 2012 to 2026
$2.2M
Patient-Oriented Research on Pseudomonas aeruginosaK24AI104831 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2013 to 2024
$1.2M
Dynamics of Pseudomonas aeruginosa During BacteremiaR21AI153953 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2020 to 2021
$435k
High-Risk Clones of Pseudomonas aeruginosaR21AI164254 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2021 to 2022
$431k
NIAID NIH HHS K24 AI104831NIAID NIH HHS R01 AI118257NIAID NIH HHS R21 AI153953NIAID NIH HHS R21 AI164254NIAID NIH HHS T32 AI007476NIAID NIH HHS T32 AI095207NIAID NIH HHS U19 AI135964
6 · The paper itself

Abstract

Hypermutator lineages of

Indexed as

COVID-19Cystic FibrosisPseudomonas InfectionsHumansPandemicsPersistent InfectionPhenotypePseudomonas aeruginosaRespiration, Artificialantibiotic resistancegenomicshypermutatorPseudomonas aeruginosavirulence

Identifiers

PMID38132670
PMCPMC10804958
OpenAlexW4390104049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.